Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, vehicle-controlled, double-blind, parallel group Phase II trial of MiCal-1 in the treatment of moderate to severe plaque psoriasis.

Next Previous
Trial Profile

A multi-centre, randomized, vehicle-controlled, double-blind, parallel group Phase II trial of MiCal-1 in the treatment of moderate to severe plaque psoriasis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CTX 101 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Ferndale Laboratories

Most Recent Events

  • 20 Sep 2017 New trial record
  • 18 Sep 2017 According to a Crescita Therapeutics media release, results will be evaluated in more detail to plan next steps in anticipation of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
  • 18 Sep 2017 Primary endpoint (Treatment success) has been met, according to a Crescita Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top